TGF-beta 3 Antibody

Name: TGF-beta 3 Antibody
Brand: R&D Systems
SKU: MAB243
Rating: 5 (1 reviews)

Catalog #: MAB243
8 Citations 1 Review Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB243-SP
MAB243-500
MAB243-100

TGF‑ beta 3 Inhibition of IL‑4-dependent Cell Proliferation and Neutralization by TGF‑ beta 3 Antibody.

2 Images

All TGF-beta 3 Antibodies

Product Details

Citations (8)

FAQs

Supplemental Products

Reviews (1)

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

TGF-beta 3 Antibody Summary

Specificity

Detects TGF-beta 3 from multiple species in direct ELISAs and Western blots. In Western blots, less than 25% cross-reactivity with recombinant human (rh) TGF‑ beta 1.2 and rhTGF-beta 2 is observed, and less than 2% cross‑reactivity with recombinant amphibian TGF-beta 5 and recombinant human TGF-beta 1 is observed. Neutralizes the biological activity of TGF-beta 3 but not TGF-beta 1, TGF-beta 2, or TGF-beta 5.

Source

Monoclonal Mouse IgG₁ Clone # 20724

Purification

Protein A or G purified from ascites

Immunogen

Spodoptera frugiperda, Sf 21 (baculovirus) derived recombinant human TGF-beta 3
Ala301-Ser412 (Tyr340Phe)
Accession # P10600

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human TGF-beta 3 (Catalog # 243-B3) under non-reducing conditions only

Immunohistochemistry

8-25 µg/mL

See below

Neutralization

Measured by its ability to neutralize TGF‑ beta 3 inhibition of IL‑4-dependent proliferation in the HT‑2 mouse T cell line. Tsang, M. et al. (1995) Cytokine 7:389. The Neutralization Dose (ND₅₀) is typically 0.1-0.3 µg/mL in the presence of 0.1 ng/mL Recombinant Human TGF‑ beta 3 and 7.5 ng/mL Recombinant Mouse IL‑4.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

TGF‑ beta 3 Inhibition of IL‑4-dependent Cell Proliferation and Neutralization by TGF‑ beta 3 Antibody. Recombinant Human TGF-beta 3 (Catalog # 243-B3) inhibits Recombinant Mouse IL-4 (Catalog # 404-ML) induced proliferation in the HT-2 mouse T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse IL-4 (7.5 ng/mL) activity elicited by Recombinant Human TGF-beta 3 (0.1 ng/mL) is neutralized (green line) by increasing concen-trations of Mouse Anti-TGF-beta 3 Monoclonal Antibody (Catalog # MAB243). The ND₅₀ is typically 0.1-0.3 µg/mL.

Immunohistochemistry

View Larger

TGF‑ beta 3 in Human Breast Cancer Tissue. TGF-beta 3 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Mouse Anti-TGF-beta 3 Monoclonal Antibody (Catalog # MAB243) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TGF-beta 3

TGF-beta 3 (transforming growth factor beta 3) is one of three closely related mammalian members of the large TGF-beta superfamily that share a characteristic cystine knot structure (1‑7). TGF-beta 1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1‑4). Each TGF‑ beta isoform has some non-redundant functions; for TGF-beta 3, mice with targeted deletion show defects palatogenesis and pulmonary development (2). Human TGF-beta 3 cDNA encodes a 412 amino acid (aa) precursor that contains a 20 aa signal peptide and a 392 aa proprotein (8). A furin-like convertase processes the proprotein to generate an N-terminal 220 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF‑ beta 3 (8, 9). Disulfide-linked homodimers of LAP and TGF-beta 3 remain non-covalently associated after secretion, forming the small latent TGF-beta 3 complex (8‑10). Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature human TGF-beta 3 shows 100%, 99% and 98% aa identity with mouse/dog/horse, rat and pig TGF-beta 3, respectively. It demonstrates cross-species activity.(1) TGF-beta 3 signaling begins with high-affinity binding to a type II ser/thr kinase receptor termed TGF-beta RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF-beta RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK-1.This complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Contributions of the accessory receptors betaglycan (also known as TGF-beta RIII) and endoglin, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-beta in different contexts (11).

References

Sporn, M.B. (2006) Cytokine Growth Factor Rev. 17:3.
Dunker, N. and K. Krieglstein (2000) Eur. J. Biochem. 267:6982.
Wahl, S.M. (2006) Immunol. Rev. 213:213.
Chang, H. et al. (2002) Endocr. Rev. 23:787.
Lin, J.S. et al. (2006) Reproduction 132:179.
Hinck, A.P. et al. (1996) Biochemistry 35:8517.
Mittl, P.R.E. et al. (1996) Protein Sci. 5:1261.
Derynck, R. et al. (1988) EMBO J. 7:3737.
Miyazono, K. et al. (1988) J. Biol. Chem. 263:6407.
Oklu, R. and R. Hesketh (2000) Biochem. J. 352:601.
de Caestecker, M. et al. (2004) Cytokine Growth Factor Rev. 15:1.
Zuniga, J.E. et al. (2005) J. Mol. Biol. 354:1052.

Long Name

Transforming Growth Factor beta 3

Entrez Gene IDs

7043 (Human); 21809 (Mouse); 25717 (Rat)

Alternate Names

ARVD; ARVD1; FLJ16571; LDS5; RNHF; TGFB3; TGFbeta 3; TGF-beta 3; TGF-beta3; TGF-beta-3; transforming growth factor beta-3; transforming growth factor, beta 3

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for TGF-beta 3 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

8 Citations: Showing 1 - 8
Filter your results:

Filter by:

Transforming Growth Factor-Beta Produced by Non-small Cell Lung Cancer Cells Contributes to Lung Fibroblast Contractile Phenotype
Authors: N Kanaji, M Yokohira, N Watanabe, N Kadowaki, S Bandoh
Anticancer Res., 2018-04-01;38(4):2007-2014.
TGF-beta3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses.
Authors: Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, Komai T, Shoda H, Miyazaki J, Fujio K, Yamamoto K
Nat Commun, 2015-02-19;6(0):6329.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization
Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids.
Authors: Yin H, Lo J, Kim J, Marsh E, Kim J, Ghosh A, Bulun S, Chakravarti D
Mol Endocrinol, 2013-04-02;27(5):726-40.
Species: Human
Sample Types: Tissue Homogenates
Applications: Western Blot
Systematic analysis of palatal transcriptome to identify cleft palate genes within TGFbeta3-knockout mice alleles: RNA-Seq analysis of TGFbeta3 Mice.
Authors: Ozturk F, Li Y, Zhu X, Guda C, Nawshad A
BMC Genomics, 2013-02-20;14(0):113.
Species: Mouse
Sample Types: Tissue Homogenates
Applications: Western Blot
An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition.
Authors: Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, Lindeman GJ, Shannon MF, Drew PA, Khew-Goodall Y, Goodall GJ
Mol. Biol. Cell, 2011-03-16;22(10):1686-98.
Species: Canine
Sample Types: Whole Cells
Applications: Neutralization
Notch Signaling Activation Suppresses v-Src-Induced Transformation of Neural Cells by Restoring TGF-beta -Mediated Differentiation
Authors: Samira Amarir, Maria Marx, Georges Calothy
PLoS ONE
Differential versican isoforms and aggrecan expression in the chicken embryo aorta.
Authors: Arciniegas E, Neves CY, Candelle D, Parada D
Anat Rec A Discov Mol Cell Evol Biol, 2004-07-01;279(1):592-600.
Species: Chicken
Sample Types: Whole Tissue
Applications: IHC
Th2 cytokine regulation of type I collagen gel contraction mediated by human lung mesenchymal cells.
Authors: Liu X, Kohyama T, Wang H, Zhu YK, Wen FQ, Kim HJ, Romberger DJ, Rennard SI
Am. J. Physiol. Lung Cell Mol. Physiol., 2002-05-01;282(5):L1049-56.
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA Development